Treatment Syndromes Dementia Movement Disorders Market Global Industry Analysis and Forecast 2031 - Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects
29 janv. 2024 11h23 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product,...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
09 nov. 2023 08h30 HE
|
PHARMA TWO B LTD
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and dopaminergic side effects...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07 nov. 2023 07h00 HE
|
Praxis Precision Medicines, Inc.
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
28 août 2023 07h00 HE
|
PHARMA TWO B LTD
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control...
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
23 avr. 2023 08h30 HE
|
PHARMA TWO B LTD
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
14 déc. 2022 10h47 HE
|
Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center
11 janv. 2022 13h10 HE
|
CenExel Clinical Research
Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site...
Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021
10 déc. 2021 11h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
15 oct. 2021 10h21 HE
|
Adhera Therapeutics, Inc.
IP Estate Grows with New Korean Patent Issued Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...